MRTX News and Press, Mirati Therapeutics Inc. From 03/05/19

SAN DIEGO , March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39 th Annual Healthcare Conference in Boston on Tuesday, March 12 th at 11:20 a.m. ET / 8:20 a.m. PT . O...

Mirati Therapeutics (NASDAQ: MRTX ): Q4 GAAP EPS of -$0.87 in-line. More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended December 31, 2018 . "Mirati made great progress in 2018 with significant advances ...

SAN DIEGO , Feb. 19, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019 . Dr. Rodney Lappe Ph.D. is retiring from the boa...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...

SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology Day in New York on Thursday, February 14 th at 11:00 a.m. ET / 8:00 a.m....

Since I have last written on Array ( ARRY ), the stock price has risen from $13.43 to $20.96 at the close of the market on 2/5/19. While this is a nice gain, the fundamentals of the company have also improved, suggesting there is much more room for this Mid-Cap biotech to run. While my last ...

NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged at 2.25% to 2.50%. The Dow Jones Industrial Average went higher by 1.77 percent to ...

SAN DIEGO , Jan. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO ® ), in Mira...

SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14 th at 1:40 p.m. MST / 12:40 p.m. ...